AEON Biopharma reports H1 2023 net loss of $33M; cash at $2.6M with going-concern doubt

AEON Biopharma, Inc.

Net loss of $33.0M for six months ended June 30, 2023 vs $7.6M loss in H1 2022.
Cash fell to $2.6M as of June 30, 2023 from $9.7M at Dec 31, 2022.
Accumulated deficit reached $507.9M; auditor notes substantial doubt about going concern.
Convertible notes total $134.4M ($73.4M current + $60.9M non-current) as of June 30, 2023.
Business combination with Priveterra closed July 21, 2023; now listed on NYSE as AEON.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.